HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells.

AbstractBACKGROUND:
Suboptimal activation of T lymphocytes by melanoma cells is often due to the defective expression of class I major histocompatibility antigens (MHC-I) and costimulatory molecules. We have previously shown that geranylgeranyl transferase inhibition (done with GGTI-298) stimulates anti-melanoma immune response through MHC-I and costimulatory molecule expression in the B16F10 murine model [1].
METHODOLOGY/PRINCIPAL FINDINGS:
In this study, it is shown that vaccination with mIFN-gand GGTI-298 pretreated B16F10 cells induces a protection against untreated tumor growth and pulmonary metastases implantation. Furthermore, using a human melanoma model (LB1319-MEL), we demonstrated that in vitro treatment with hIFN-gamma and GGTI-298 led to the up regulation of MHC-I and a costimulatory molecule CD86 and down regulation of an inhibitory molecule PD-1L. Co-culture experiments with peripheral blood mononuclear cells (PBMC) revealed that modifications induced by hIFN-gamma and GGTI-298 on the selected melanoma cells, enables the stimulation of lymphocytes from HLA compatible healthy donors. Indeed, as compared with untreated melanoma cells, pretreatment with hIFN-gamma and GGTI-298 together rendered the melanoma cells more efficient at inducing the: i) activation of CD8 T lymphocytes (CD8+/CD69+); ii) proliferation of tumor-specific CD8 T cells (MelanA-MART1/TCR+); iii) secretion of hIFN-gamma; and iv) anti-melanoma specific cytotoxic cells.
CONCLUSIONS/SIGNIFICANCE:
These data indicate that pharmacological treatment of melanoma cell lines with IFN-gamma and GGTI-298 stimulates their immunogenicity and could be a novel approach to produce tumor cells suitable for vaccination and for stimulation of anti-melanoma effector cells.
AuthorsGuillaume Sarrabayrouse, Christine Pich, Raphaël Moriez, Virginie Armand-Labit, Philippe Rochaix, Gilles Favre, Anne-Françoise Tilkin-Mariamé
JournalPloS one (PLoS One) Vol. 5 Issue 2 Pg. e9043 ( 2010) ISSN: 1932-6203 [Electronic] United States
PMID20140259 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD86
  • Benzamides
  • Cytokines
  • GGTI 298
  • Histocompatibility Antigens Class I
  • Interferon-gamma
Topics
  • Animals
  • Antigens, CD86 (immunology, metabolism)
  • Benzamides (pharmacology)
  • Blotting, Western
  • Cell Line, Tumor
  • Coculture Techniques
  • Cytokines (metabolism)
  • Cytotoxicity, Immunologic (immunology)
  • Female
  • Flow Cytometry
  • Histocompatibility Antigens Class I (immunology, metabolism)
  • Humans
  • Interferon-gamma (pharmacology)
  • Jurkat Cells
  • Leukocytes, Mononuclear (cytology, immunology, metabolism)
  • Melanoma (immunology, metabolism, pathology)
  • Melanoma, Experimental (immunology, pathology)
  • Mice
  • Mice, Inbred C57BL
  • T-Lymphocytes (immunology, metabolism)
  • Up-Regulation (drug effects)
  • Vaccination (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: